Research
Hormonal
Quercetin supplementation (100-150 mg/day) significantly reduces body fat percentage and BMI in overweight or obese adults, likely by modulating adipokine expression and oxidative stress.
If you are overweight, taking 100-150 mg of quercetin daily for 12 weeks may help reduce body fat and BMI. While results vary by individual genetics (APOE), it is a low-risk intervention worth trying alongside standard diet and exercise.
ModerateSupportsMEDIUM confidence
In a 12-week, randomized, double-blind, placebo-controlled study, Lee et al. demonstrated that quercetin (100 mg/day/subject) significantly decreased the total body fat, particularly in the percentage of fat in the arm, and decreased the body mass index (BMI) of overweight or obese subjects [54]. Another study evaluated the effects of quercetin on obesity in overweight-obese subjects with various apolipoprotein E (APOE) genotypes; the authors reported that quercetin (150 mg/day/subject) decreased the waist circumference and triacylglycerol concentration [55].
Why this rating
Based on limited human clinical trials (n=2 cited) with mixed results (one negative study cited).
Source
The Beneficial Effects of Quercetin, Curcumin, and Resveratrol in Obesity
Yueshui Zhao et al. · Oxidative Medicine and Cellular Longevity · 2017
DOI 10.1155/2017/1459497
narrative_reviewCited 208×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Curcumin supplementation (1g/day with piperine) improves metabolic markers like triglycerides and inflammatory cytokines in obese individuals, though it does not significantly change body weight or BMI.Moderate
- Resveratrol (150 mg/day) increases energy expenditure and reduces inflammatory markers in obese men, but higher doses (1500 mg/day) may be ineffective for these outcomes.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →